At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed Nov 9, 2026 at 16:06 ET
Coherus reported Q3 2026 net revenue of $14.3M, up 23% YoY, and a non-GAAP net loss of $(0.20) per share, beating the consensus estimate of $(0.21). The company announced a strategic prioritization of tagmokitug in esophageal cancer, a ~30% headcount reduction, and guided to lower quarterly cash burn of $6M-$7M. Cash and equivalents fell to $83.6M from $172.1M at year-end 2025.
- Q3 2026 net revenue $14.3M vs $11.6M YoY (+23%)
- Non-GAAP EPS $(0.20) vs consensus $(0.21) (beat)
- LOQTORZI net revenue $14.0M, up 25% YoY
- Headcount reduction of ~30% to lower core cash burn by $6M-$7M quarterly
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access